secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYOMO, INC. (MYO)
CIK:        0001369290
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0000950170-24-027949
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myomo Q4 revenue $4.8M (+18% YoY), backlog record 230 units, guides FY2024 rev $28M-$30M
--------------------------------------------------------------------------------

- Q4 product revenue $4.756M (+18% YoY); recognized 107 MyoPro units (+6%).
- Net loss $2.5M ($0.07/shr) vs $2.2M ($0.29/shr) in Q4 2022; adjusted EBITDA -$2.1M.
- Record backlog 230 units (+40% YoY), including 44 Medicare Part B patients receiving rental payments or qualified.
- Q1 2024 revenue guidance $4.1M-$4.3M; full year 2024 revenue target $28M-$30M with operating cash flow breakeven targeted by Q4.
- CMS finalized HCPCS fees for MyoPro codes L8701 ($33,480.90) and L8702 ($65,871.74) effective April 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369290/000095017024027949/0000950170-24-027949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369290/000095017024027949/myo-20240307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-027949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer